200
Participants
Start Date
April 5, 2024
Primary Completion Date
May 31, 2026
Study Completion Date
December 31, 2026
Ubrogepant
Ubrogepant (Ubrelvy™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Rimegepant
Rimegepant (Nurtec®), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Atogepant
Atogepant (Qulipta™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Eptinezumab
Eptinezumab (Vyepti®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Fremanezumab
Fremanezumab (Ajovy®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Galcanezumab
Galcanezumab (Emgality®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Erenumab
Erenumab (Aimovig®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Botulinum toxin A
Botolinum toxin A (Botox) injections into extracranial muscles, dosage at discretion of clinical provider, for treatment of migraines.
Cleveland Clinic, Main Campus, Cleveland
The Cleveland Clinic
OTHER